ELL CRANELL

ELL CRANELL is a German hair-loss brand owned by the dermatology company Galderma. Its core product is a medicated scalp solution containing alfatradiol, a compound related to the hormone estradiol, and Wikipedia describes the name as the trade name of two hair-loss treatments in Germany [8]. Unlike most brands on a beauty shelf, it is a licensed medicine rather than a cosmetic: the solution is restricted to pharmacies, though it can be bought there without a prescription.

The brand is notable less for a founding story, which is not documented, than for the debate around its active ingredient. Galderma presents the solution as a clinically backed answer to inherited hair loss in both men and women, while independent assessments of alfatradiol have been considerably more cautious. The brand remains active, with a dedicated consumer website maintained by Galderma's German subsidiary.

When the ELL CRANELL name was first used, and whether Galderma created the brand or took it over from another company, is not stated in any available source. The earliest firm date attached to the brand belongs to its main product. According to the official product information, the 250 micrograms per millilitre alfatradiol solution received its first German marketing authorisation on 26 February 1996 [5]. That authorisation was last renewed on 18 September 2001. These are approval dates for a medicine, not a documented founding date for the brand itself.

The product's legal home is Galderma Laboratorium GmbH in Düsseldorf, the German subsidiary that holds the marketing authorisation and publishes the brand's consumer website [6]. Düsseldorf is therefore the seat of the company responsible for the brand in Germany rather than a headquarters specific to ELL CRANELL.

A 2016 trade-press article summed up the brand's starting point in one line: the name originally stood for a solution built on alfatradiol. Everything else that later carried the ELL CRANELL name grew out of that single medicine.

For most of its documented life, ELL CRANELL was a one-product brand. Alongside the main solution, Wikipedia records a second treatment sold under the name Ell-Cranell dexa, which combined alfatradiol with the corticosteroid dexamethasone [9]. That combination was prescription-only and was intended for mild to moderate inherited hair loss in younger women, according to an entry citing the 2005 edition of the German drug directory Rote Liste.

The brand drew wider attention in 2010. That year the German consumer magazine Öko-Test examined 30 hair-loss products, ranging from prescription drugs to food supplements and cosmetics, and rated close to two-thirds of them "poor" or "unsatisfactory". Reporting on the test, the pharmacy trade publication APOTHEKE ADHOC noted that the testers considered the effectiveness of alfatradiol medicines poorly proven, naming ELL CRANELL from Galderma and a competing product, Pantostin, as the alfatradiol drugs on the market [11]. The article did not state an individual grade for ELL CRANELL.

From the mid-2010s, Galderma began to stretch the name beyond medicine. Around 2015 it introduced Ell-Cranell Re-Balance, a hair-loss solution based on onion, lemon, guarana and cocoa rather than a drug ingredient. In 2016 the Re-Balance line was extended with two capsule products, both sold as "Haarfülle+", one for men and one for women [12].

Those capsules had a history of their own. They were former products of Innéov, a food-supplement brand set up in 2002 as a joint project between L'Oréal and Nestlé, with Nestlé developing the ingredients and L'Oréal handling sales and marketing. Innéov was launched first in France and two years later in Germany, but it never became a commercial success there and disappeared from German pharmacies in 2015. Roughly 18 months after that, Galderma brought two of its products back under the ELL CRANELL umbrella. APOTHEKE ADHOC reported that the revived capsules were identical in content and price to the Innéov originals, and that it was not known why Galderma chose not to revive the old name. Innéov itself remained on sale in Spain, Portugal, Italy and Brazil at the time.

The relaunch carried a small irony. In the same 2010 Öko-Test review that questioned alfatradiol, the Innéov Haarfülle supplement had been rated "unsatisfactory" because of missing data on its effectiveness [11]. Six years later, the product returned under a brand originally built on that same alfatradiol solution.

To promote the relaunch, Galderma ran a cash-back campaign for buyers of a three-month treatment. Participants had to send in their receipt and complete a questionnaire, which asked how satisfied they were, whether they would recommend the product, and whether they had previously bought rival treatments such as Regaine, Priorin or Pantovigar.

ELL CRANELL belongs to Galderma, and in Germany it is managed by Galderma Laboratorium GmbH [6]. How and when the brand came into Galderma's hands is not documented.

Galderma's own ownership history forms the backdrop to the brand's later expansion. According to APOTHEKE ADHOC, Galderma was founded in 1981 as a joint venture, and in 2014 L'Oréal handed its stake in that venture to Nestlé as part of a wider deal in which Nestlé reduced its shareholding in L'Oréal [12]. The end of Innéov was set in motion in the same year, and both former partners kept the right to use its knowledge and property rights in their own fields of business, which provides the background to former Innéov products later reappearing under a Galderma brand.

On Galderma's German brand portal, ELL CRANELL sits alongside a mix of skincare, prescription and aesthetic brands. These include Cetaphil, Benzaknen, Actinica and Excipial, as well as Loceryl, Nubral, Tannolact, Restylane and Sculptra.

ELL CRANELL positions itself as a medical answer to a specific problem. Its tagline, "Haarausfall immer richtig behandeln", translates roughly as "always treat hair loss the right way", and the company frames its offering around the idea that different kinds of hair loss have different causes.

The brand's central focus is hereditary, hormone-related hair loss, known medically as androgenetic alopecia. On its consumer site, the company explains that this type of hair loss stems from an inherited oversensitivity of the hair roots to dihydrotestosterone, or DHT, a hormone produced in the body from testosterone. According to the brand, DHT shortens the growth phase of the hair, so that each new hair grows back thinner and softer and falls out sooner. Galderma also presents the product for diffuse hair loss, a more general thinning across the scalp.

Two themes run through the brand's messaging. The first is that the treatment is described as equally suitable for men and women. The second is patience. Galderma tells users that the first results should not be expected before 12 weeks, because that is how long hair needs to grow back, and calls patience the single most important factor for the treatment to work.

The company also stresses convenience. It describes the solution as acting directly at the hair root, as well tolerated, and as needing to be applied only once a day. The brand's site adds that the liquid is neither sticky nor greasy, so a hairstyle can stay in place after use.

The brand's flagship is ELL-CRANELL mit Alfatradiol, a 250 micrograms per millilitre scalp solution. It is sold in a 100 ml bottle and in multi-packs of three 100 ml or three 200 ml bottles, and it is classed as a pharmacy-only medicine available without a prescription. The solution is applied once daily to the affected areas of the scalp with an applicator that the company describes as patented, although no patent number is given.

According to the official product information, the active ingredient alfatradiol, also called 17α-estradiol, is a stereoisomer of the female sex hormone 17β-estradiol: a molecule with the same building blocks arranged in a different spatial form [5]. The brand explains that alfatradiol blocks 5-alpha reductase, the enzyme that converts testosterone into DHT, and so reduces the effect of DHT directly at the oversensitive hair root. The company also states that, although derived from a female hormone, alfatradiol does not act like an estrogen in the body and does not interfere with the body's own hormonal balance. Wikipedia, by contrast, classifies the compound as a weak estrogen as well as a 5-alpha reductase inhibitor, and lists Ell-Cranell Alpha among its trade names [10].

Other products have used the ELL CRANELL name over the years. The prescription combination Ell-Cranell dexa paired alfatradiol with dexamethasone. Under the Re-Balance sub-line, Galderma sold the onion-, lemon-, guarana- and cocoa-based solution and, from 2016, the Haarfülle+ capsules for men and women. Galderma's current German brand page presents only the alfatradiol solution, and whether the dexa and Re-Balance products are still sold is unclear.

The scientific case for ELL CRANELL rests on its active ingredient, and here the brand's own statements and independent sources diverge.

The official product information states that clinical studies showed a clear increase in the proportion of hairs in the active growth phase in the front and top of the scalp compared with a placebo, with no difference between men and women [5]. On its consumer site, the brand goes further: it says the treatment led to less hair loss in 80 % of users along with visibly more and thicker hair, and that four out of five users confirm the treatment worked [7]. These figures are the company's own claims.

Independent sources paint a more modest picture. Wikipedia's article on alfatradiol describes a university-led study in 103 women that compared alfatradiol with minoxidil, another topical hair-loss treatment, and found minoxidil to be more effective [10]. In that study, alfatradiol did not increase hair density or thickness; it only slowed down or stabilised hair loss. Wikipedia also notes that, as with other hair-loss drugs, the solution has to be used continuously to prevent further hair loss, and that regrowth of hair already lost is possible only to a limited extent.

The 2010 Öko-Test assessment, which judged the effectiveness of alfatradiol medicines poorly proven, points in the same direction [11]. Taken together, the sources show a clear gap between the brand's claim of more and thicker hair and the more cautious independent evidence on the ingredient.

ELL CRANELL is an active brand. Its consumer website, haarausfall.de, carries a 2026 copyright notice from Galderma Laboratorium GmbH and mandatory product information dated November 2023, and the brand is listed among the company's brands on Galderma's German brand portal. The alfatradiol solution remains the brand's main product. Available sources describe ELL CRANELL chiefly as a German pharmacy medicine, sold through brick-and-mortar and online pharmacies.